Getting FDA approval for a product is only one part of the battle for pharma and biotech companies. There are many milestones for drugmakers to navigate on the path to launching a new drug or treatment, whether it’s a new-to-market product or an existing asset that’s gained an additional indication. Four distinct components need to be carefully mapped out by the launch team to bring a new drug to market successfully.
In this paper, we walk you through these four critical components, the requirements, and timeline for each:
1. Where to Play
2. How to Win
3. How to Execute
4. The Launch Plan
Vice President of Commercialization
Partner, Chief Operating Officer
We have experience in more than 75 launches, spanning cell & gene therapy, oncology, rare disease, diabetes, obesity, infectious disease, CNS and trauma.
Complete the form to receive this whitepaper.